

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN TECHNOLOGIES, INC.,  
Petitioner,

v.

MONOSOL RX, LLC,  
Patent Owner.

---

Case IPR2017-00200  
Patent 8,603,514

---

DECLARATION OF ROBERT S. LANGER, Sc.D.

Mylan v. MonoSol  
IPR2017-00200  
MonoSol Ex. 2007

## Table of Contents

I.	INTRODUCTION .....	1
II.	SCOPE OF THIS DECLARATION .....	2
III.	MATERIALS CONSIDERED .....	3
IV.	SUMMARY OF QUALIFICATIONS .....	3
V.	COMPENSATION .....	8
VI.	LEGAL STANDARDS AND LEVEL OF SKILL .....	8
	A. Petitioner’s Burden Of Proof.....	8
	B. Person Of Ordinary Skill In The Art.....	8
	C. Obviousness.....	11
	D. Claim Construction.....	12
VII.	SUMMARY OF OPINIONS .....	13
VIII.	REVIEW OF THE DISCLOSURES OF THE ’514 PATENT .....	15
	A. The ’514 Patent .....	15
	1. The ’514 Patent Claims At Issue .....	15
	2. The Problem Addressed By The ’514 Patent.....	19
	3. Drug Migration Was Generally Not A Problem When Unit Doses Were Made In Individual Molds That Prevent Migration To Other Dosing Units.....	22
	4. The ’514 Patent Distinguishes Approaches In Which Unit Doses Are Made In Individual Wells From The DCU Problem Addressed In The Patent .....	23
	5. A POSA Would Understand The Claims Of The ’514 Patent, Under Their Broadest Reasonable Construction, As Directed To Individual Unit Doses That Are Taken From A Single Film Matrix .....	23
	a. The Panel’s Statement On Construction In The Decision To Institute .....	24
	b. The Express Language Of The Claims Concerns A Film Matrix Subdivided Into Individual Unit Doses.....	25

c.	Understanding The Claims As Limited To A Multi-Dose Film Is The Only Interpretation Consistent With The Specification .....	26
d.	The Specification Clearly Identifies The Preparation Of Unit Doses In Individual Molds As An “Alternative” To The Claimed Invention .....	30
e.	The File History Also Indicates The Claims Are Directed To The Multi-Dose Film Interpretation.....	31
6.	The 10% Drug Content Uniformity Limitation: Substantially Equally Sized Individual Unit Doses Which Do Not Vary By More Than 10% Of The Desired Amount Of Active.....	31
IX.	THE ’514 PATENT CLAIMS WERE NOT OBVIOUS OVER ILANGO AND CHEN .....	33
A.	State Of The Art At The Date Of Invention.....	35
1.	Pharmaceutical Films Were A Relatively New Dosage Form .....	35
2.	Little Was Known About The Causes Of Loss Of Drug Content Uniformity In Individual Dosing Units Taken From A Single Matrix, Much Less Solutions For That Problem .....	36
3.	Prior Art Films Dr. Buckton Discusses Do Not Mention DCU .....	44
a.	The Roddy, Frankman, Brode References .....	45
b.	The Suzuki Reference.....	48
c.	The Tapolsky And Yamamura References.....	49
d.	The Heller Reference.....	50
e.	The Schiraldi, Loesche And Zaffaroni References .....	50
f.	The Bess, Schmidt And Higashi References.....	51
4.	The Swei Reference .....	56
B.	Publications That Post-Date The Invention Of The ’514 Patent Acknowledge The Problems It Addressed And Confirm It Was A Novel Solution.....	59

1.	V.A. Perumal et al., “Investigating A New Approach to Film Casting For Enhanced Drug Content Uniformity In Polymeric Films,” <i>Drug Dev. &amp; Indust. Pharm.</i> , 34:1036–1047 (2008) (“Perumal 2008,” Ex. 2005).....	61
2.	V. A. Perumal, “Multipolymeric Monolayered Mucoadhesive Films For Drug Therapy,” Master’s Thesis (2007) (“Perumal Thesis”; Ex. 2009).....	70
3.	Morales et al., “Manufacture And Characterization Of Mucoadhesive Buccal Films,” <i>European Journal Of Pharmaceutics And Biopharmaceutics</i> , 77:187–199 (2011) (“Morales 2011”; Ex. 2003).....	77
4.	Morales et al., “The Influence Of Recrystallized Caffeine On Water-Swellable Polymethacrylate Mucoadhesive Bucca Films,” <i>AAPS PharmSciTech</i> , Vol. 14, No. 2, 475–484 (2013) (“Morales 2013”; Ex. 2010).....	80
C.	Deficiencies In The Ilango And Chen References Cited By Dr. Buckton .....	82
1.	Ilango et al., “In-Vitro Studies On Buccal Strips Of Glibenclamide Using Chitosan,” <i>Indian J. Pharm. Sci.</i> 59:232–35 (1997) (“Ilango”; Ex. 1005).....	83
a.	What Ilango Discloses Generally .....	88
b.	Ilango Lacks Clear Descriptions Of Its Methods And Its Disclosure Is Insufficient To Allow Reproduction.....	89
c.	Ilango Provides No Evidence That The Drug Remained In Particle Form, As Opposed To Being Dissolved.....	92
d.	Ilango Provides No Teaching Of How To Utilize Viscosity To Solve DCU, And That Ilango Relies On Evaporation At Room Temperature And Does Not Add Heat In Drying Underscores That Ilango Is Not Addressing The DCU Problem Solved By The ’514 Patent.....	98

e.	Ilango’s Teachings Related To Making Unit Doses Individually In Molds Would Not Lead A Person Of Ordinary Skill To The Claimed Invention, Which Requires A Multi-Dose Film From Which Multiple Individual Unit Doses Are Taken .....	99
f.	There Is No Evidence That Ilango’s Statement About Content Variation Related To A “Desired Amount” Of Drug In Each Strip Dosage Unit, Much Less That The Drug Content Of The Strips Varied By Less Than 10% Of That Amount .....	102
2.	Chen Application WO2000/42992 (“Chen”; Ex. 1006).....	109
D.	The ’514 Patent Claims Are Not Obvious Over Ilango And Chen.....	118
1.	There Was No Motivation For A Person of Ordinary Skill To Combine Ilango And Chen .....	119
2.	A Person Of Ordinary Skill Would Not Have Reasonably Expected That The Combination Of Ilango And Chen Would Lead To The Invention Of The ’514 Patent Claims .....	122

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.